欢迎来到上海通蔚!

021-54845833/15800441009

品质保证 · 通蔚试剂

当前位置: 首页 > 科研产品 > 科研抗体 > 一抗 > 兔抗NOG多克隆抗体
  • 兔抗NOG多克隆抗体

    规格:
    数量:

    购买数量

    价格:
    • 品牌 : 通蔚生物
    • 目录号 : TW20888
    • 应用 : 仅供科研使用
    • 保存条件 : 低温保存
    • 货期 : 现货
    • 商品库存:80
  • 商品详情
  • 参考文献
  • 说明书下载
  • 商品评论0
  • 相关产品

中文名称: 兔抗NOG多克隆抗体


英文名称: Anti-NOG rabbit polyclonal antibody


别       名: noggin; SYM1; SYNS1; SYNS1A


相关类别: 一抗


储       存: 冷冻(-20℃)


宿      主: Rabbit


抗      原: NOG


反应种属: Human, Mouse


标  记  物: Unconjugate


克隆类型: rabbit polyclonal


技术规格

Background:

The secreted polypeptide, encoded by this gene, binds and inactivates members of the transforming growth factor-beta (TGF-beta) superfamily signaling proteins, such as bone morphogenetic protein-4 (BMP4). By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, this protein may have a principal role in creating morphogenic gradients. The protein appears to have pleiotropic effect, both early in development as well as in later stages. It was originally isolated from Xenopus based on its ability to restore normal dorsal-ventral body axis in embryos that had been artificially ventralized by UV treatment. The results of the mouse knockout of the ortholog suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. Recently, several dominant human NOG mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) were identified; both SYM1 and SYNS1 have multiple joint fusion as their principal feature, and map to the same region (17q22) as this gene. All of these mutations altered evolutionarily conserved amino acid residues. The amino acid sequence of this human gene is highly homologous to that of Xenopus, rat and mouse.

Applications:

ELISA, IHC

Name of antibody:

NOG

Immunogen:

Synthetic peptide of human NOG

Full name:

noggin

Synonyms:

SYM1; SYNS1; SYNS1A

SwissProt:

Q13253

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human gastric cancer and Human liver cancer

IHC Recommend dilution:

25-100